[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 245
Citations 0
Capitol Health Call
July 12, 2016

Senators Urge Expedited Evaluation of Medical Use of Cannabidiol

JAMA. 2016;316(2):140. doi:10.1001/jama.2016.8699

Sen Chuck Grassley (R, Iowa) and Sen Dianne Feinstein (D, Calif) have asked Attorney General Loretta Lynch and Health and Human Services (HHS) Secretary Sylvia Burwell for the Department of Justice and HHS to work together to remove barriers to the scientific and medical evaluation of cannabidiol (CBD), an active ingredient of marijuana.

Many people suffer from serious medical conditions that might be alleviated by CBD, so it is “critical” that such an evaluation be completed to determine whether there is a scientific basis to make CBD a legal controlled substance while keeping marijuana illegal under federal law, wrote Grassley and Feinstein, chair and co-chair, respectively, of the Senate’s Caucus on International Narcotics Control (http://1.usa.gov/1WwMvH8; http://1.usa.gov/1sLHOg2).

First Page Preview View Large
First page PDF preview
First page PDF preview
×